logo
What Chinese propaganda says about Albo

What Chinese propaganda says about Albo

Yahoo16-07-2025
Anthony Albanese's visit to China has gone down well with the country's state media, offering insight into Beijing's true feelings about the future of its relationship with Canberra.
The Global Times is a leading English-language propaganda mouthpiece for the Chinese Communist Party (CCP).
Doing its best to imitate a Western-style publication, it is often used to circulate the CCP's various pet peeves and routinely takes scathing shots at Australia.
But the Chinese government tabloid had only good things to say after the Prime Minister's meet with Xi Jinping and other party top brass.
An 'opinion' piece published on Wednesday said the meetings 'set the tone for steady progress in bilateral ties while keeping external disruptions at bay' — a swipe at the US.
'The turnaround in China-Australia relations reflects the genuine expectations of both peoples,' the unattributed piece said.
'It also demonstrates that China and Australia are opportunities for each other's development – and highlights the strong appeal of China's vast market, the resilience of its economic growth, and the certainty of its continued commitment to opening up.'
It acknowledged but glossed over sore spots in the relationship, such as the Port of Darwin.
Mr Albanese vowed during the election to break the 99-year lease to Chinese logistics giant
Landbridge Holdings.
The Global Times previously described the pledge as a 'drastic step' and 'ethically questionable'.
Mr Albanese also said after meeting Mr Xi that the Chinese leader did not raise the port, suggesting it may have dropped off Beijing's top-tier grievances.
'Of course, compared with the 'minefields' status described by the Global Times editorial three years ago, today's China-Australia relationship is like a plane flying in the 'stratosphere' after passing through the storm zone, and the most turbulent and bumpy period has passed,' the opinion piece said.
The Chinese have waged a charm offensive on Mr Albanese's six-day trip, with officials and business leaders wooing him in the glitz of central Shanghai before his high-level talks in Beijing.
He has in turn spruiked Australia's trade and tourism offerings.
Though, despite best efforts on both sides to keep things positive, chasmic differences remain.
Against a backdrop of China's rapid military build-up, Mr Albanese has kept firmly to his mantra of co-operating where 'we can' and disagreeing where 'we must'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Yahoo

time3 minutes ago

  • Yahoo

Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia

Launch complements existing Tweed and Spectrum Therapeutics product portfolio SMITHS FALLS, Ontario, August 05, 2025--(BUSINESS WIRE)--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. "Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options," said Andrew Bevan, SVP, Global Medical. "With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia." "Global medical is one of Canopy Growth's largest commercial opportunities," said Luc Mongeau, Chief Executive Officer. "Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform." The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. About Canopy GrowthCanopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ("Canopy USA"). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. For more information visit View source version on Contacts Alex ThomasDirector, Tyler BurnsDirector, Investor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

China's independent oil companies boost investments in Iraq
China's independent oil companies boost investments in Iraq

Yahoo

time3 minutes ago

  • Yahoo

China's independent oil companies boost investments in Iraq

Chinese independent oil companies are intensifying their activities in Iraq, aiming to double their production to 500,000 barrels per day (bpd) by 2030, according to a Reuters report. This strategic move comes as some global majors have scaled back from these markets, which are traditionally dominated by China's state-run entities. The smaller Chinese producers, led by industry veterans, are drawn to Iraq by more attractive contract arrangements and the potential to leverage lower costs and faster project development. Geo-Jade Petroleum, United Energy Group, Zhongman Petroleum and Natural Gas Group, and Anton Oilfield Services Group have secured half of Iraq's exploration licences in recent rounds. Currently, China's CNPC is a major player, responsible for more than half of Iraq's production at large oilfields such as Haifaya, Rumaila and West Qurna 1. These companies are recognised for their rapid project execution, which appeals to the Iraqi Government. Their increasing presence signifies a shift for Iraq, which is under pressure to expedite energy projects and has previously resisted increasing Chinese influence over its oilfields. Furthermore, the agility and risk tolerance of these smaller companies allow them to develop oilfields in two to three years, significantly faster than Western counterparts. Iraq's improved political stability and investment climate are cited by executives as key factors in attracting both Chinese and Western companies. The country is seeking to significantly boost its oil output, targeting more than six million barrels per day by 2029. Iraq's shift from fixed-fee agreements to profit-sharing contracts has been instrumental in attracting Chinese independents. Geo-Jade Petroleum CEO Dai Xiaoping was quoted as saying: 'Chinese independents have much lower management costs compared to Western firms and are also more competitive versus Chinese state-run players.' Despite concerns over transparency and technical standards, the cost-effective approach of Chinese companies remains attractive to Iraq. While some Western companies are making a comeback, with TotalEnergies and bp planning significant investments, the trend of Chinese operators' expansion in Iraq's oil sector is clear. In May, a consortium spearheaded by Geo-Jade decided to fund the South Basra endeavour, encompassing the enhancement of the Tuba field in Iraq's southern region to a capacity of 100,000bpd. This included the construction of a refinery capable of processing 200,000bpd. With an investment pledge of $848m (6.09bn yuan), Geo-Jade is set to rejuvenate production at the predominantly idle field, aiming to achieve production of 40,000bpd by mid-2027. "China's independent oil companies boost investments in Iraq" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

US-China tensions offer new opportunity for APAC biotechs, report suggests
US-China tensions offer new opportunity for APAC biotechs, report suggests

Yahoo

time3 minutes ago

  • Yahoo

US-China tensions offer new opportunity for APAC biotechs, report suggests

Investors are increasingly focused on biotech companies outside of China operating in the Asia-Pacific (APAC) market, according to a report by management consulting firm Bain & Company. Homing in on Singapore specifically, the report states that rising players within the APAC region are drawing in investors through their political neutrality, protection of intellectual property (IP) and strong healthcare infrastructure. This trend is further driven by continued investment by the Singaporean Government, which has handed out $25bn in early-stage funding between 2021 and 2025 through its Research Innovation and Enterprise 2025 (RIE2025) scheme. Singapore is also aiming to bridge the gap between academia and industry through its A*STAR scheme, which is designed to encourage the translation of research into commercially viable drugs. These initiatives are designed to de-risk the early-stage development process, laying the foundations for future venture capital investment. Changing tides in the biotech sector The 2020s have been a tough period for the biotech industry, with many companies failing to obtain funding amid growing geopolitical instability and a sharpened investor focus on late-stage therapies. However, things may be looking up for the sector, with a GlobalData report finding that biotech companies obtained $8.52bn in 2024 through initial public offerings (IPOs) — a marked increase from the $5.06bn raised in 2023. Though the US and China continue to dominate the market, rising tensions between the nations could shift the balance towards politically neutral and stable nations, stated Alison Labya, senior pharma business fundamentals analyst at GlobalData. Labya said: 'Singapore's alignment with international pharmaceutical standards reduces legal and regulatory risk, increasing investor confidence in the commercial potential of innovative drugs." As the US continues to face geopolitical uncertainty, NIH funding cuts and mass regulatory layoffs, Labya noted that APAC players — particularly Singapore — are emerging as attractive alternatives for biotech investors, offering a more stable environment conducive to bringing drugs to market. Biotech's future moving forward Even amidst the growing geopolitical tensions between the US and China, Labya stated that China will likely remain the dominant force in Asian biotech. 'China remains resilient in the face of Trump's trade war, notably retaliating with 125% tariffs on US goods in April 2025,' Labya commented. Through this response, both countries reduced their import tariff rates, highlighting China's capacity to influence trade and policy outcomes. Large pharma has also continued to engage with the Chinese biotech market, with 28% of innovator drugs now being picked up from the nation, according to a report from GlobalData. For APAC countries such as Singapore to compete with China, Labya noted that biotechs in the region must penetrate the US and EU, requiring expertise into the FDA and EMA's regulatory frameworks, as well as the development of international partnerships. "US-China tensions offer new opportunity for APAC biotechs, report suggests" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store